Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can masks and air purifiers shield COPD patients from wildfire smoke?

NCT ID NCT07118189

Disease control Sponsor: Kaiser Permanente Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This pilot study tests whether giving N95 masks and indoor air cleaners to 20 older adults with COPD can reduce lung flare-ups during poor air quality from wildfires. Participants are Kaiser Permanente members aged 65+ who use oxygen. The study focuses on whether this approach is practical and acceptable, not yet on health outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
N95 masks and indoor air cleaner
What this could lead to
If successful, this could show that simple protective devices help people with COPD avoid serious lung attacks during wildfire season.
What could go wrong
This is a very small pilot study (20 people) focused on feasibility, not proof of effectiveness. Results may not apply to all COPD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * KPNC patients * enrolled in Care Plus * non-smoking * oxygen-dependent * adults aged ≥65 years old * have had membership for at least 1 year prior to data extraction not counting \</=3mo gaps) * have known COPD (at least 2 encounters with COPD ICD codes over a 3 year period in the 10 years prior to data extraction using the following ICD codes: ICD-9 491.21, 491.22, 491.8, 491.9, 492.8, 493.2, 493.21, 493.22, 496 and ICD-10 J44.1, J44.0, J41.8, J44.9, J42)15 * have picked up at least 1 controller inhaler at the pharmacy within 1 year prior to data extraction * at least 2 exacerbations of COPD treated in any setting (outpatient or acute care) within 1 year before to data extraction. Exclusion Criteria: * with \<1 year of continuous membership prior to the date they entered the cohort, allowing for 3-month, non-contiguous gaps * any diagnosis with any of the past or present problems: blindness, dementia, deaf or hearing impaired, hospice admission, "tracheostomy" procedure code or problems and/or attached to a ventilator * hearing, visually, physically, memory, and/or speech impaired * those on the "Do Not Call" list * non-English speakers.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease (COPD) Exacerbation of chronic obstructive pulmonary disease Exacerbation of COPD

Contacts and locations

Locations

  • Kaiser Permanente Northern California Division of Research

    Pleasanton, California, 94588, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.